Series date: 
01/01/2025 - 7:30am to 12/31/2025 - 8:30am

COURSE DIRECTOR
Ladan Zand, M.D.

DESCRIPTION
Each week, a fellow selects an article from a relevant journal to discuss.  The expectation is to ask a consultant to review the article choice and assist in the discussion of the article.  One week prior to the conference, the journal article is electronically distributed to division members.  

A short background review of pertinent information is presented during the conference.  Following this, the chosen article as well as its strengths and weaknesses is analyzed using evidence based medicine principles.  This contributes to the discussion and understanding of the selected manuscript.

On select dates, a fellow will be requested to share a Point-of-Care-Ultrasound Mini-Case for 5 minutes at the beginning to our Journal Club Conference.

Live-Streamed; Weekly on Friday from 7:30-8:30 a.m.

TARGET AUDIENCE
Allied Health Professionals, Nurses, Nurse Practitioners, Physicians, Physician Assistants, Resident Fellows, and Scientist Researcher PhDs. 

LEARNING OBJECTIVES
Upon completion of this activity, participants should be able to:

  • Identify how to apply clinical practice updates to improve patient outcomes.
  • Review clinical and basic research literature using an evidence-based approach.
  • Debate if specific findings are relevant and applicable to patient care.

Accreditation Statement
In support of improving patient care, Mayo Clinic College of Medicine and Science is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Statement(s):
AMA
Mayo Clinic College of Medicine and Science designates this live activity for a maximum of 1.00 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DISCLOSURE SUMMARY
As a provider accredited by Joint Accreditation for Interprofessional Continuing Education, Mayo Clinic College of Medicine and Science must ensure balance, independence, objectivity and scientific rigor in its educational activities.  All who are in a position to control the content are required to disclose all financial relationships with any ineligible company.   Faculty will also identify any off-label and/or investigational use of pharmaceuticals or instruments discussed in their content for FDA compliance.

Listed below are individuals with control of the content of this program who have disclosed...

Relevant financial relationship(s) with ineligible companies:

Hatem Amer, M.D. - Honoraria - Novartis Pharmaceuticals Corporation; Research Grant - Kaneka Pharma 
Ladan Zand, M.D. - Honoraria - Calliditas NA Enterprises, Inc., Calliditas Therapeutics, Otsuka Pharmaceutical Co., Inc., Travere Therapeutics, Inc., Genentech, Inc., Vera Therapeutics

All relevant financial relationships have been mitigated. 

No relevant financial relationship(s) with ineligible companies: 
Iasmina Craici, M.D.
Diane Chicos (Coordinator)
Kathleen Hegna Zelinske (Coordinator)
Jacqlyn Parker (Coordinator)

References to off-label usage(s) of pharmaceuticals or instruments in their presentation:
None

ATTENDANCE / CREDIT
Text the session code (provided only at the session) to 507-200-3010 within 48 hours of the live presentation to record attendance. All learners are encouraged to text attendance regardless of credit needs. This number is only used for receiving text messages related to tracking attendance. Additional tasks to obtain credit may be required based on the specific activity requirements and will be announced accordingly. Swiping your badge will not provide credit; that process is only applicable to meet GME requirements for Residents & Fellows.

TRANSCRIPT
Any credit or attendance awarded will appear on your Transcript.

For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s) and staff, please go here to review disclosures.

QUESTIONS?
Contact Kathy Hegna Zelinske at phone 6-1044 OR Jacqlyn Parker at phone 4-3479

Where did the idea for the course originate?: 
Minnesota

Sessions

Session Date
Nephrology and Hypertension Journal Club Small molecule APOL1 inhibitors as a precision medicine approach for APOL1-mediated kidney disease February 21 2025 02/21/2025 - 7:30am to 8:30am
Nephrology and Hypertension Journal Club Small Glucarpidase for Treatment of High-Dose Methotrexate Toxicity February 28 2025 02/28/2025 - 7:30am to 8:30am
Nephrology and Hypertension Journal Club Clonal hematopoiesis of indeterminate potential is associated with acute kidney injury March 14 2025 03/14/2025 - 7:30am to 8:30am
Nephrology and Hypertension Journal Club Circulating Angiogenic Factor Levels in Hypertensive Disorders of Pregnancy March 21 2025 03/21/2025 - 7:30am to 8:30am
Nephrology and Hypertension Journal Club Cell free DNA for the detection of kidney allograft rejection March 28 2025 03/28/2025 - 7:30am to 8:30am
Nephrology and Hypertension Journal Club Effect of Continuing Versus Withholding SGLT2 Inhibitors on Incidence of Contrast Associated AKI in Patients Undergoing Coronary Angiography April 18 2025 04/18/2025 - 7:30am to 8:30am
Nephrology and Hypertension Journal Club Oral Semaglutide and Cardiovascular Outcomes in High Risk Type 2 Diabetes April 25 2025 04/25/2025 - 7:30am to 8:30am
Nephrology and Hypertension Journal Club Stopping Versus Continuing Metformin in Patients with Advanced CKD A Nationwide Scottish Target Trial Emulation Study May 2 2025 05/02/2025 - 7:30am to 8:30am
Nephrology and Hypertension Journal Club Presentation and outcome in carries of pathogenic variants in SLC34A1 and SLC34A3 encoding sodium phosphate transporter NPT 2a and 2c May May 9 2025 05/09/2025 - 7:30am to 8:30am
Nephrology and Hypertension Journal Club Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis May 16 2025 05/16/2025 - 7:30am to 8:30am

Pages